INDICATIONS

RINVOQ is indicated for the treatment of active ankylosing spondylitis (AS) in adults who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation in adults who have had an inadequate response or intolerance to TNF blocker therapy.

Limitations of Use: RINVOQ is not recommended for use in combination with other Janus kinase (JAK) inhibitors, biologic disease-modifying antirheumatic drugs (bDMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.